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Reduced N -acetyl-aspartate (NAA) levels have been reported in the prefrontal cortex (PFC)
in patients with schizophrenia using proton magnetic resonance spectroscopy. However,
it is unclear whether this NAA reduction predates the illness onset and is reported in
subjects at-risk for developing schizophrenia (HRS). The aim of this study was to assess
NAA levels in the PFC in HRS. We hypothesized that HRS display lower NAA levels than
healthy controls in the PFC. Studies assessing levels of NAA/Creatine (NAA/Cr) in the PFC
in HRS were extracted from literature. Meta-analysis tools were used to compute effect
sizes of nine selected studies meeting our inclusion criteria (clinical and/or genetic HRS,
groups of HRS, and healthy controls matched for age and gender, spectral acquisition in
the PFC). We reported that HRS exhibited a significant lower NAA/Cr level (2.15±0.29;
n=208) than healthy controls (2.21±0.32; n= 234) in the PFC with a medium pooled
effect size [Hedges’s g =−0.42; 95% confidence interval: (−0.61; −0.23); p< 0.0001] cor-
responding to an average 5.7% of NAA/Cr decrease. Secondary analysis revealed that this
reduction was observed in young HRS (<40 years old) who have not reached the peak age
of risk for schizophrenia (−11%, g =−0.82, p<0.00001) but not in old HRS (>40 years old)
who have already passed the peak age (g =0.11, p=0.56), when they are compared with
their matched healthy controls. Our findings suggest that the NAA/Cr reduction in the PFC
reported in patients with schizophrenia is observable only in HRS who have not passed the
peak age of risk for schizophrenia. NAA/Cr level in the PFC could therefore be considered
as a biological vulnerability marker of schizophrenia.
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INTRODUCTION
The prefrontal cortex (PFC) is crucially involved in schizophre-
nia (1). Morphological and functional abnormalities have been
reported in the PFC at different stages of the illness (2, 3). Neu-
rochemical substrates of these abnormalities can be investigated
in vivo by assessing brain metabolite concentrations with pro-
ton Magnetic Resonance Spectroscopy (1H-MRS). Amongst the
brain metabolites measured with 1H-MRS, the N -acetyl-aspartate
(NAA) is a metabolite reflecting neuronal health or viability (4).
NAA is the second most abundant metabolite in the Human brain
and emits the strongest signal in 1H-MRS. NAA is detected in
the adult brain only in neurons. Its precise functions are still
under investigation, ranging from osmolyte to fluid balance in
the brain, source of acetate for myelin synthesis, contributor
to energy production in mitochondria, and precursor for N -
Acetylaspartylglutamic acid (NAAG) synthesis. NAA decreases
have been detected in several human disorders involving neuronal
loss or dysfunction such as Alzheimer disease, epilepsy, amy-
otrophic lateral sclerosis, multiple sclerosis, AIDS, traumatic brain
injury, Rett syndrome, mood disorder, stroke, and non-neuronal
brain tumors such as glioma. In a recent review and metaanalysis
of 64 studies including 1256 patients and 1209 healthy controls,
Steen and colleagues (5) have reported a 10% NAA reduction in
the PFC in patients with schizophrenia, compared with healthy
controls. Such a NAA reduction may reflect neuronal or axonal
loss and may account for neuronal and molecular perturbations
leading to abnormal brain activity often reported in patients with
schizophrenia (6). Reduced NAA levels in the PFC have also been
observed in patients during acute stages of the illness (7) and in
stabilized patients (8). Moreover, reduced NAA levels in the PFC
have been associated with poor prognosis across the first years of
the illness (9). Antipsychotic medication have been reported to
modulate NAA concentration leading to the hypothesis that the
changes observed in NAA levels in the PFC in patients may be due
primarily to treatment (10).
According to the neurodevelopmental model of schizophrenia
(11), some abnormalities predate the illness onset by several years.
These abnormalities, considered as vulnerability markers of schiz-
ophrenia, are observed in ill, stabilized, and recovered patients
with schizophrenia, as well as in individuals at high risk for schiz-
ophrenia [HRS; (12)]. HRS are either defined as clinical high-risk
subjects or genetic high-risk subjects and are generally young
adults or teenagers. Clinical high-risk subjects are people who
developed a brief psychotic episode (<7 days) resolved without
any intervention or people who exhibited schizotypal traits, i.e.,
subthreshold non-clinical psychotic symptoms. Genetic high-risk
subjects are first or second-degree relatives of patients with schiz-
ophrenia, more frequently unaffected siblings of patients (13).
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Finally, HRS can also present the two types of risk: a genetic
risk for psychosis coupled with deterioration in global functioning
over the past year (Genetic Risk and Deterioration Syndrome). In
HRS, the risk to develop the illness reaches a peak between 15 and
30 years old (it is admitted that the peak age of risk is reached at age
25) and then decreases with aging until 40 (14). After 40, the risk
to develop the illness is considered as low and already passed. HRS
displayed behavioral, cognitive, and brain abnormalities when they
are compared with healthy subjects (15). Abnormalities observed
in HRS usually have an intermediate magnitude between the frank
deficit reported in patients with schizophrenia and “normal” func-
tioning observed in healthy subjects. For instance, unaffected sib-
lings of patients displayed cognitive abnormalities similar to those
seen in probands but at lower intensity [e.g. (13, 16)]. Depending
on the stability of their magnitude across the different stages of
the illness, these abnormalities can be considered as trait, state,
or intermediate vulnerability markers (16). Some morphological
(17) and functional (18) brain abnormalities have been reported
in the PFC in HRS. However, chemical substrates of such abnor-
malities remains unclear and 1H-MRS studies investigating NAA
levels in the PFC in HRS led to inconsistent results. The aim of
the current study was to investigate NAA levels in the PFC in
HRS. To achieve this goal, we reviewed 1H-MRS studies assessing
NAA levels in the PFC in HRS compared with healthy controls. We
hypothesized that HRS displayed lower NAA levels in the PFC than
healthy controls, suggesting an alteration in neuronal integrity in
the PFC before the onset of frank psychotic episode and long-term
medication intake. Since aging influences the risk to develop schiz-
ophrenia (13, 14), we hypothesized that NAA levels were especially
lower in younger HRS who have not passed the peak age of risk
for schizophrenia.
MATERIALS AND METHODS
SELECTION OF STUDIES AND EXCLUSION CRITERIA
A systematic search of the literature was conducted using Pubmed
and Sciencedirect databases until March 2013. The article iden-
tification was based on various combinations of the following
keywords: (“NAA” OR “N -acetylaspartate” OR “N -Acetylaspartic
acid”) AND (“at-risk” OR “vulnerability” OR “liability” OR
“ARMS”) AND (“schizophrenia”OR“psychosis”OR“schizotypy”)
AND (“spectroscopy” OR “MRS”). The search was limited to orig-
inal English-written articles related to research in human subjects.
This primary search yielded 11 articles and was completed by a
manual search from references cited in primarily found articles.
This secondary search yielded 20 articles.
1H-MRS studies require selection of a voxel for spectrum acqui-
sition. Many studies in HRS acquire spectra from different brain
regions or subregions and with different voxel sizes, leading to dif-
ficulties in comparing findings. In order to tabulate NAA levels in
a way that would enable us to compare between studies, only stud-
ies expressing or allowing to compute NAA concentrations as a
ratio to creatine (Cr) were included. Cr represents components of
the cell’s energy metabolism and is assumed to remain relatively
constant. Moreover, only studies investigating at least HRS and
healthy control groups matched for gender and age were included.
Among the selected articles, nine studies were excluded for not
reporting original data in HRS (n= 6) and/or for not reporting
NAA/Cr in our region of interest, the PFC (n= 3). Two studies
were excluded because the group of HRS and the group of healthy
controls were not matched for age.
A final total of nine articles were retained for analysis. Char-
acteristics of studies are described in Table 1 (participants
demographical characteristics and volume of the voxel placed
in the PFC for 1H-MRS acquisition). The study of Jessen and
colleagues (19) included two different groups of HRS accord-
ing to the German Research Network on Schizophrenia criteria
(20): early at-risk subjects (ER) and late at-risk subjects (LR).
These two groups of subjects were considered separately in our
analysis.
EFFECT SIZE CALCULATION AND DATA ANALYSIS
Comparisons between groups were realized using two-tailed
paired Student’s t -test for age and chi square Fischer’s exact test
for gender.
Effect sizes were computed as the standardized mean difference
and standard deviation between HRS and their matched control
Table 1 | Characteristics of studies included in the analysis.
HRS Healthy controls Voxel (cm3)
Age (years) SD age M/F Age (years) SD age M/F
Keshavan et al. (21) 15.1 2.7 5/4 14.3 5.4 6/4 3
Callicott et al. (22) 34.6 8.6 25/35 32.9 8.2 42/24 PFC
Brooks et al. (23) 11.0 1.7 9/7 10.8 1.7 6/6 8
Block et al. (24) 49.2 15.4 19/16 40.2 15.3 7/12 30
Tibbo et al. (25) 16.4 2.0 7/13 16.7 1.7 9/13 2.5
Jessen et al. (19) (ER) 27.0 6.8 5/5 34.8 13.5 17/7 30
Jessen et al. (19) (LR) 28.7 7.0 4/5 34.8 13.5 17/7 30
Purdon et al. (26) 46.3 6.1 2/13 43.5 6.75 3/11 15.6
Yoo et al. (27) 22.6 5.3 12/10 23.1 4.8 13/9 6
Lutkenhoff et al. (28) 49.5 10.0 7/5 55.7 3.8 6/15 8
Total 31.1 7.3 95/113 29.5 6.1 126/108 –
Cr, creatine; ER, early risk; HRS, high-risk subjects; LR, late-risk; M/F, number of male/female; NAA, N-acetyl-aspartate; voxel, voxel size in cm3; SD, standard deviation.
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groups in each study. An individual corrected effect size for each
study was calculated (29), and a combined (pooled weighted)
effect size was obtained through the implementation of a random
effect model. According to Cohen (30), an effect size of 0.2 can be
considered as small, 0.5 as medium, and 0.8 as large. Significance
of effect sizes was assessed using two-tailed Student’s t -tests with
a significance set at p< 0.05.
Effect of aging
Since aging influences the risk to develop schizophrenia [decrease
of risk between 30 and 40; less risk after 41 years old; (13, 14)] as
well as NAA levels [between before and after 40 years old; (31)],
secondary analyses were conducted for studies reporting a mean
age of HRS group older than 40 (who have already passed the peak
age of risk for schizophrenia) and studies reporting a mean age of
HRS group younger than 40.
RESULTS
The final sample was composed by 208 HRS (clinical and/or
genetic HRS) and 234 healthy controls. Studies investigated NAA
and Cr levels in the whole PFC (22) or in a voxel of variable dimen-
sions placed in the PFC (21), the left PFC (19, 23, 24, 28), the left
dorsolateral PFC (27), the right and left medial PFC (26), or the
right medial PFC (25). Characteristics of studies were reported in
Table 1.
No difference in age was reported between the HRS group
(mean= 31.05± SD= 7.26) and the healthy control group
(29.55± 6.07; Student’s t -test, p= 0.97). No difference in gender
proportion was reported between the two groups (95 males and
113 females in the HRS group versus 126 males and 108 females
in the healthy control groups, Chi square test, p= 0.10).
Seven of the selected studies did not show an individual sig-
nificant difference between HRS and healthy controls [(19, 21, 24,
25) ER subgroup; (26, 27, 28)]. Three studies reported individual
differences between groups [(19, 22, 23) LR subgroup]. Details are
given in Table 2.
Compared with healthy controls, HRS displayed a significant
5.7% reduction of NAA/Cr in the PFC (see Figure 1; Table 2).
The mean NAA/Cr was significantly lower in the HRS group
(2.15± 0.29) than in the healthy controls group (2.28± 0.32).
The random effect model showed a significant medium pooled
effect size of−0.42 [95% confidence interval (CI): (−0.61;−0.23);
p< 0.0001].
EFFECT OF AGING
Three studies reported a mean age of subjects older than 40 (24,
26, 28). When these studies were removed, HRS exhibited a sig-
nificant 11% reduction of NAA/Cr in the PFC. NAA/Cr was lower
in younger HRS (2.12± 0.29; n= 146) than in younger controls
(2.38± 0.32;n= 180) with a large pooled effect size of−0.82 [95%
CI: (−1.08;−0.62); p< 0.000001]. In studies reported a mean age
of subjects older than 40, NAA/Cr was not different between HRS
(1.96± 0.28; n= 62) and healthy controls (1.93± 0.27; n= 54)
with an effect size of 0.11 [95% CI: (−0.26; 0.47); p= 0.56].
DISCUSSION
We conducted an analysis on 9 studies assessing NAA/Cr level in
the PFC in HRS (10 groups) and in matched healthy controls. We
reported a significant 5.7% reduction of NAA/Cr in HRS com-
pared with healthy controls. The effect size of this reduction was
medium (g =−0.42). Secondary analyses revealed a large effect
size between HRS who have not reached the peak age of risk for
schizophrenia (g =−0.82) and their matched healthy controls.
Conversely, no difference was reported between HRS who have
already passed the peak age of risk for schizophrenia (older than
40) and their matched healthy controls (g = 0.11). These results
suggest that NAA/Cr in the PFC is reduced only in young HRS.
Noteworthy, the NAA/Cr reduction reported in the PFC in young
HRS (−11%) seems similar to the reduction reported in patients
with schizophrenia [−10%; (5)]. These results did not corroborate
results from the metaanalysis of Brugger et al. (32), which reported
no difference in NAA/Cr level between HRS and healthy controls.
Table 2 | Effect size of studies investigating NAA/Cr in high-risk subjects for schizophrenia and healthy controls.
HRS Healthy controls Hedges’s g 95% CI p*
Mean n SD Mean n SD Lower Upper
Keshavan et al. (21) 1.1 9 0.27 1.14 10 0.24 −0.15 −1.05 0.75 0.74
Callicott et al. (22) 2.66 60 0.38 2.81 66 0.37 −0.40 −0.75 −0.05 0.03*
Brooks et al. (23) 1.67 16 0.22 1.92 12 0.31 −0.93 −1.71 −0.14 0.02*
Block et al. (24) 2.76 35 0.37 2.93 19 0.35 −0.46 −1.03 0.10 0.11
Tibbo et al. (25) 1.74 20 0.20 1.67 22 0.20 0.34 −0.27 0.95 0.26
Jessen et al. (19) (ER) 2.8 10 0.27 3.01 24 0.34 −0.64 −1.39 0.12 0.09
Jessen et al. (19) (LR) 2.54 9 0.33 3.01 24 0.34 −1.36 −2.19 −0.53 0.001*
Purdon et al. (26) 1.67 15 0.24 1.57 14 0.13 0.50 −0.24 1.24 0.18
Yoo et al. (27) 1.3 22 0.23 1.37 22 0.13 −0.37 −0.96 0.23 0.22
Lutkenhoff et al. (28) 1.47 12 0.24 1.29 21 0.32 0.60 −0.13 1.32 0.10
Total 2.15 208 0.29 2.28 234 0.32 −0.42 −0.61 −0.23 0.0001*
*Significant difference, two-tailed Student’s t-test.
CI, confidence interval; ER, early risk; HRS, high-risk subjects; LR, late-risk; n, sample size; SD, standard deviation.
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FIGURE 1 | Levels of NAA/Cr in the prefrontal cortex of high-risk
subjects compared with healthy controls (random-effects model). The
horizontal line represents the confidence interval for each study, and each
square represents the point estimate. The size of the square corresponds to
the weight of the study. The diamond represents the pooled effect size
estimate in the whole HRS sample (black diamond), in young HRS (i.e., who
have not reached the peak age of risk for schizophrenia; <40), and in old
HRS (i.e., who have already passed the peak age of risk for schizophrenia;
>40) (gray diamonds).
We assume that discrepancies between results can be explained
by the difference in age of participants. Indeed, the metaanalysis
conducted by Brugger and colleagues took into account studies
including HRS who have passed the peak of risk for developing
schizophrenia (24, 26, 28) and studies including groups of HRS
and healthy controls that were not matched for age (33, 34).
Several limitations have to be acknowledged in our study. First,
the volume and placement of the voxel used for assessing NAA
levels were widely different amongst the included studies, from
the whole PFC (22) to a voxel of 2.5 cm3 (25). Although this
approach may mask findings that are specific to a particular subre-
gion of the PFC, it has been reported in patients with schizophrenia
that NAA findings were similar within each subregion of the PFC
(5). Second, the power of the magnetic field used to acquire 1H-
MRS spectra differed across the studies [3T 1H-MRS scan: (25,
26, 28), versus 1.5T in the other studies]. However, this differ-
ence was addressed by expressing NAA as a ratio to Cr instead
of raw concentrations (35, 36). As shown in Table 2, there are
wide variations in NAA/Cr ratios among studies (from 1.1 to 3.01
in the healthy subjects group and from 1.1 to 2.80 in the HRS
group). This discrepancy may have resulted from methodological
differences in 1H-MRS acquisitions (e.g., voxel size, power of the
magnetic field). However, such variations may not have impact the
comparison between groups of HRS and healthy controls since val-
ues were normalized between matched groups (5). In the sample of
HRS, some patients were treated with antipsychotic medication. It
was not possible to split HRS into treated versus untreated based on
information provided in the papers reviewed. Since antipsychotic
are known to modulate NAA level in patients with schizophrenia
(10), we cannot exclude an effect of medication on NAA level in
our sample of participants. However, it seems that antipsychotic
increased NAA level in patients with schizophrenia (37), thus the
observed reduction in NAA/Cr in HRS cannot be explained by
antipsychotic intake in HRS. A last limit consists in the hetero-
geneity of HRS samples included in the studies (e.g., offspring and
siblings of patients with schizophrenia, subjects with prodromal or
subthreshold clinical symptoms, subjects who will develop or have
already developed other Axis I psychopathology, clinical high-risk
subjects or subjects with a combination of different risk). Here
again, it was not possible to split the sample in groups according
to their level of risk based on information provided in the stud-
ies. This inherent limitation to our approach ecologically reflects
the heterogeneity of HRS. Finally, even if the sample sizes of the
included studies were rather limited, our final sample size can be
considered as large enough to detect a 5.7% difference (208 HRS
and 234 healthy control, statistical power 100%).
Hence, we reported that NAA/Cr in the PFC was lower in HRS
than in healthy controls, especially in young HRS. This result sug-
gests that the NAA/Cr reduction predates the onset of the illness
and is not present in HRS who have already passed the peak age
of risk for developing schizophrenia. This result is in line with
studies reporting reduced prefrontal NAA/Cr in adolescents with
first episode psychosis who later progress to schizophrenia but
not in those who later progress to other disorders (38) or do not
develop any psychiatric condition. The magnitude of the reduc-
tion was also proposed to be an early marker of outcome in first
psychotic episode (9, 33). Thus, the NAA/Cr reduction in the PFC
seems to be accurately detectable at each stage of the illness and
to be specific to schizophrenia. Therefore it can be considered as a
vulnerability marker of schizophrenia.
The NAA reduction may reflect a neuronal loss and/or dysfunc-
tion and may be linked to early neuronal damage, supporting the
neurodevelopmental hypothesis of schizophrenia. However, some
studies have reported an exacerbation of the NAA/Cr decrease in
the PFC during the first years of the illness following the onset of
psychosis (8,39). The exacerbation of NAA/Cr reduction following
the onset of the illness suggests an additional brain degener-
ative process superimposed on the developmental impairment
(7, 40, 41).
CONCLUSION
In sum, the NAA/Cr reduction observed in the PFC of HRS may be
proposed as a biological marker of vulnerability to schizophrenia.
Further longitudinal studies can help us determine if NAA/Cr in
the PFC is able to predict transition to schizophrenia. Moreover,
studies targeting other brain areas and/or other 1H-MRS mea-
surable metabolites implicated in schizophrenia can propose pat-
terns of metabolic alterations helpful to decipher physiological
hypotheses.
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